OOIR: Observatory of International Research

Papers

(The H4-Index of CNS Drugs is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond	160
Post-COVID-19 Depressive Symptoms: Epidemiology, Pathophysiology, and Pharmacological Treatment	115
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies	92
Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status	92
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview	81
Intranasal Insulin for Alzheimer’s Disease	79
Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies	67
A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia	65
Pharmacology of Cenobamate: Mechanism of Action, Pharmacokinetics, Drug–Drug Interactions and Tolerability	61
Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox–Gastaut Syndrome	61
Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression	59
Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis	58
A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication	54
Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability	54
Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analys	53
Pharmacological Treatments for Borderline Personality Disorder: A Systematic Review and Meta-Analysis	52
Cannabis-Based Medicines and Medical Cannabis for Chronic Neuropathic Pain	52
Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score	51
Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders	49
Expanding the Treatment Landscape for Lennox-Gastaut Syndrome: Current and Future Strategies	46
High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis	43
Efficacy and Safety of HSK3486 for Anesthesia/Sedation in Patients Undergoing Fiberoptic Bronchoscopy: A Multicenter, Double-Blind, Propofol-Controlled, Randomized, Phase 3 Study	41
Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis	39
Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex)	38
Using the Intranasal Route to Administer Drugs to Treat Neurological and Psychiatric Illnesses: Rationale, Successes, and Future Needs	38

Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis	38
Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status	37
Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia	36
The Potential of N-Acetyl-L-Cysteine (NAC) in the Treatment of Psychiatric Disorders	35
The Evolution of Medication Overuse Headache: History, Pathophysiology and Clinical Update	33
Antipsychotic-Induced Constipation: A Review of the Pathogenesis, Clinical Diagnosis, and Treatment	32
Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST)	31
Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder	31
The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review	31
Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment	31
Improving the Delivery of Levodopa in Parkinson’s Disease: A Review of Approved and Emerging Therapies	31